The pharmaceutical manufacturing industry in Connecticut is a critical segment focused on producing medicines and therapeutic products. This sector includes a mix of contract manufacturers, biotech firms, and companies specializing in vaccine development. As the demand for innovative drugs and preventive solutions rises, these companies are investing heavily in research, fostering collaborations to enhance their offerings. An emphasis on compliance and quality control drives operational standards, underlining a commitment to safety. The future appears promising, with advancements in technology and a growing trend towards personalized medicine setting the stage for emerging opportunities within the industry.

This list highlights 19 pharmaceutical manufacturing companies based in Connecticut, showcasing various aspects such as company size, establishment years, and specializations. Ranging in size from small startups, like Simcha Therapeutics with 1-10 employees, to larger entities like TriRx Pharmaceutical Services with up to 500 employees, these companies contribute significantly to the health sector. Established from 1956 to 2020, they focus on diverse domains including vaccines, peptides, and drug delivery systems, demonstrating a rich tapestry of expertise in pharmaceuticals.

Read on to discover the top pharmaceutical manufacturing companies in Connecticut.

Top 19 Pharmaceutical Manufacturing Companies in Connecticut

1. TriRx Pharmaceutical Services, LLC

• Website: trirx.com
• Ownership type: Private
• Headquarters: Norwalk, Connecticut, United States (USA)
• Employee distribution: United States (USA) 59%, United Kingdom (UK) 23%, France 18%
• Founded year: 2019
• Headcount: 201-500
• LinkedIn: trirx

TriRx Pharmaceutical Services, LLC, based in Norwalk, Connecticut, is a contract development and manufacturing organization (CDMO) that specializes in pharmaceutical manufacturing. Founded in 2019, TriRx offers a wide array of services, including the development and production of oral solid doses, semi-solids, liquids, and biologics. The company operates multiple facilities across the United States and Europe, including locations in Huntsville, Alabama; Shawnee, Kansas; Segré, France; and Speke, Liverpool, UK. TriRx is dedicated to delivering high-quality products while ensuring compliance with stringent regulatory standards. Their team, composed of industry veterans, emphasizes transparency and integrity in their operations, aiming to foster long-term partnerships with clients in the pharmaceutical sector. TriRx's commitment to operational excellence and customer service further enhances their position in the pharmaceutical manufacturing industry.

2. Protein Sciences Corporation

• Website: proteinsciences.com
• Ownership type: Corporate
• Headquarters: Meriden, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $650.0M, July 2017
• Founded year: 1983
• Headcount: 51-200
• LinkedIn: protein-sciences-corporation

Protein Sciences Corporation, based in Meriden, Connecticut, is a pharmaceutical company founded in 1983. It specializes in the development and distribution of vaccines, with a strong emphasis on influenza prevention. The company is known for its flagship products, Fluzone and Flublok, which are designed to provide effective immunization against influenza A and B viruses. Fluzone is approved for use in individuals as young as six months, while Flublok is targeted at adults aged 18 and older. Notably, Flublok utilizes recombinant technology, which enhances its efficacy and safety profile compared to traditional vaccines. The company has received significant funding, amounting to $650 million in 2017, which underscores its potential for growth and innovation in the vaccine sector. Protein Sciences Corporation operates entirely within the United States, focusing on providing essential immunization solutions to healthcare professionals and organizations.

3. Imbrium Therapeutics

• Website: imbriumthera.com
• Ownership type: Private
• Headquarters: Stamford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2018
• Headcount: 11-50
• LinkedIn: imbrium-therapeutics

Imbrium Therapeutics L.P., based in Stamford, Connecticut, is a clinical-stage biopharmaceutical company founded in 2018. The company is dedicated to advancing medical science by developing important new therapeutics aimed at serious medical conditions. Imbrium operates within the biopharmaceutical industry, focusing on areas such as oncology, central nervous system disorders, and non-opioid pain management. Their pipeline includes investigational therapies like Tinostamustine, which is in Phase II trials for oncology, and Sunobinop, currently in Phase I trials for various indications. As a subsidiary of Purdue Pharma L.P., Imbrium is committed to collaborating with both commercial and academic partners to enhance drug development efforts. Their work is centered on addressing significant unmet patient needs, making them a notable entity in the pharmaceutical sector.

4. Kleo Pharmaceuticals Inc.

• Website: kleopharmaceuticals.com
• Ownership type: Corporate
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: $20.0M, January 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn: kleo-pharmaceuticals-inc.

Kleo Pharmaceuticals Inc. is a pharmaceutical company based in New Haven, Connecticut, established in 2015. The company is dedicated to developing innovative drug candidates aimed at addressing unmet medical needs in the fields of neuroscience, immunology, and oncology. Kleo Pharmaceuticals is actively involved in clinical trials, working on treatments for conditions such as obsessive-compulsive disorder (OCD), epilepsy, and spinal muscular atrophy (SMA). With a workforce of 11-50 employees, the company operates with a patient-centric approach, emphasizing the importance of scientific advancement in drug discovery and development. In January 2021, Kleo Pharmaceuticals secured $20 million in funding, which underscores its commitment to advancing its therapeutic pipeline and enhancing its capabilities in drug development.

5. Vanessa Research, Inc.

• Website: vanessaresearch.com
• Ownership type: Private
• Headquarters: Hamden, Connecticut, United States (USA)
• Founded year: 2014
• Headcount: 51-200
• LinkedIn: vri

Vanessa Research, Inc., now operating as Vanessa Biotech, is a biomedical company based in Hamden, Connecticut. Founded in 2014, the company is dedicated to creating innovative healthcare solutions for rare diseases. Their primary focus is on developing pharmaceuticals, with Shylicine™ being their flagship product designed to treat microvillus inclusion disease (MVID). This condition is particularly challenging, as it causes severe diarrhea in infants, often requiring intravenous nutrition. Vanessa Biotech is not just a research entity; they have made significant strides in pharmaceutical manufacturing by acquiring HG Biotech, which enhances their ability to produce and supply their medications. This acquisition positions them to better serve patients with rare diseases and to ensure the quality of their products. The company is also involved in various research initiatives and has received orphan drug designation for Shylicine™, indicating regulatory support for their efforts in this critical area of healthcare.

6. Tower Laboratories, Ltd.

• Website: towerlabs.com
• Ownership type: Private
• Headquarters: Essex, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1979
• Headcount: 201-500
• LinkedIn: tower-laboratories-ltd.

Tower Laboratories, Ltd. is a private company based in Essex, Connecticut, established in 1979. The firm specializes in the manufacturing of effervescent products, including tablets, powders, and granulations. They provide contract manufacturing services to various sectors, including pharmaceuticals, dietary supplements, and cosmetics. Tower Laboratories prides itself on its compliance with FDA regulations and its commitment to cGMP standards, ensuring that their products meet high-quality benchmarks. With a workforce of approximately 138 employees, the company operates multiple facilities across Connecticut and Michigan, totaling over 220,000 square feet of manufacturing space. Their capabilities extend to product development, packaging, and private label services, making them a versatile partner for businesses looking to innovate in the effervescent product market.

7. BioXcel, LLC

• Website: bioxcel.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Employee distribution: India 90%, United States (USA) 10%
• Founded year: 2005
• Headcount: 51-200
• LinkedIn: bioxcel-corporation

BioXcel, LLC, based in Guilford, Connecticut, is a biopharmaceutical company founded in 2005. The firm specializes in developing transformative medicines, particularly in the fields of neuroscience and immuno-oncology, utilizing advanced artificial intelligence technology. Their proprietary AI platform, EvolverAI, enhances the efficiency of drug discovery and development processes, allowing for faster and more cost-effective solutions to unmet medical needs. BioXcel has made significant strides in the industry, notably with the FDA approval of IGALMI™ (dexmedetomidine), an orally dissolving sublingual film designed for the acute treatment of agitation associated with schizophrenia and bipolar disorders. This product highlights BioXcel's commitment to addressing critical health challenges. The company operates with a workforce that is predominantly based in India, reflecting a global approach to its operations and research capabilities. BioXcel's innovative strategies and successful product development underscore its relevance in the pharmaceutical manufacturing sector.

8. Simcha Therapeutics

• Website: simchatx.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $40.0M, January 2022
• Founded year: 2018
• Headcount: 1-10
• LinkedIn: simcha-therapeutics

Simcha Therapeutics is a clinical-stage biotechnology company based in New Haven, Connecticut, founded in 2018. The company specializes in developing novel immunotherapies aimed at treating cancer. Their approach centers on engineered cytokines, which are proteins that play a vital role in regulating the immune system. One of their most advanced programs is ST-067, an innovative immunotherapy that targets interleukin-18 (IL-18) pathways to counteract immune checkpoints in the tumor microenvironment. This focus on harnessing immune biology reflects their commitment to transforming scientific discoveries into effective cancer treatments. Simcha Therapeutics has attracted significant investment, securing $40 million in Series B funding in January 2022, which underscores their potential in the biotech space and their ongoing efforts to bring new therapies to market.

9. Normunity

• Website: normunity.com
• Ownership type: Private Equity
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $75.0M, January 2025
• Founded year: 2020
• Headcount: 11-50
• LinkedIn: normunity

Normunity is a biotechnology company based in New Haven, Connecticut, founded in 2020. The company specializes in developing precision medicines and cancer immunotherapies, utilizing proprietary platforms to uncover novel mechanisms that disrupt normal immune responses in cancer. Their primary focus is on creating a new class of cancer treatments known as immune normalizers, which aim to enhance the body's natural immune response against cancer. Normunity collaborates closely with the Yale School of Medicine, leveraging academic insights to drive their drug discovery efforts. The company has recently secured $75 million in Series B funding, reflecting strong investor interest in their innovative approach to cancer treatment. With a small team of around 21 employees, Normunity is positioned to make significant strides in the field of oncology.

10. ChemWerth Inc.

• Website: chemwerth.com
• Ownership type: Family Owned
• Headquarters: Woodbridge, Connecticut, United States (USA)
• Employee distribution: United States (USA) 62%, China 38%
• Founded year: 1982
• Headcount: 51-200
• LinkedIn: chemwerth-inc

ChemWerth Inc., founded in 1982 and based in Woodbridge, Connecticut, is a family-owned pharmaceutical development company that specializes in the supply of active pharmaceutical ingredients (APIs). With a workforce of approximately 116 employees, ChemWerth has built a reputation for its expertise in new product development, compliance audits, and regulatory support for pharmaceutical manufacturers. The company operates an FDA-approved laboratory where it formulates and validates methods to ensure the quality of its products. ChemWerth has successfully filed over 200 Drug Master Files (DMFs) globally, demonstrating its capability in navigating complex regulatory environments. Their commitment to high standards is reflected in their extensive compliance programs, which include routine audits of partner factories to ensure adherence to cGMP standards. ChemWerth's strategic partnerships with manufacturers across the globe allow them to offer a wide range of products, catering to both human and veterinary markets. Their mission is to provide reliable, high-quality APIs while supporting their clients in achieving market readiness efficiently.

11. Cybrexa Therapeutics

• Website: cybrexa.com
• Ownership type: Venture Capital
• Headquarters: New Haven, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Series B, $25.0M, March 2021
• Founded year: 2017
• Headcount: 11-50
• LinkedIn: cybrexa-therapeutics

Cybrexa Therapeutics, founded in 2017 and based in New Haven, Connecticut, is a biotechnology company dedicated to developing innovative cancer treatments. The company specializes in peptide-drug conjugates, utilizing its proprietary alphalex technology platform to improve the delivery of anti-cancer agents directly to tumor cells. This approach aims to enhance the efficacy of existing therapies while minimizing side effects. Cybrexa is currently advancing its lead candidate, CBX-12, through clinical trials, with promising results reported in various solid tumors. The company has successfully raised $25 million in Series B funding as of March 2021, which supports its ongoing research and development efforts. With a focused mission to revolutionize cancer treatment, Cybrexa is positioned to make a significant impact in the oncology field.

12. LAM Therapeutics

• Website: lamtherapeutics.com
• Ownership type: Private
• Headquarters: Guilford, Connecticut, United States (USA)
• Latest funding: $40.0M, February 2016
• Founded year: 2013
• Headcount: 1-10
• LinkedIn: lam-therapeutics

LAM Therapeutics, based in Guilford, Connecticut, is a biotechnology firm established in 2013. The company is dedicated to developing breakthrough therapeutics aimed at treating cancer and rare diseases. Their portfolio includes several clinical-stage programs, notably LAM-001, an inhaled mTOR kinase inhibitor for lymphangioleiomyomatosis, LAM-002, a PIKfyve kinase inhibitor for B-cell non-Hodgkin lymphoma, and LAM-003, an immune-modulating drug for acute myeloid leukemia. LAM Therapeutics employs advanced technologies, including genome editing and deep learning, to enhance drug discovery and patient treatment matching. The company has successfully raised significant funding, including $40 million in 2016 and $58 million in 2017, to support its clinical programs and operational growth. Their focus on precision medicine and innovative treatment options positions them as a notable player in the biotechnology sector.

13. ApiJect Systems

• Website: apiject.com
• Ownership type: Private
• Headquarters: Stamford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 74%, United Kingdom (UK) 17%, Switzerland 6%, Other 3%
• Latest funding: Other (Grant), $425,000, October 2024
• Founded year: 2016
• Headcount: 51-200
• LinkedIn: apiject

ApiJect Systems, Corp. is a private medical device manufacturer based in Stamford, Connecticut, founded in 2016. The company specializes in innovative drug delivery systems utilizing Blow-Fill-Seal (BFS) technology. ApiJect partners with pharmaceutical and biotechnology firms to improve the efficiency of filling and finishing injectable products. Their offerings include prefilled injectors and a range of manufacturing services tailored to the needs of their partners. ApiJect's platform allows for the scalable production of single-dose prefilled injectors, which are essential for the delivery of vaccines and other injectable medications. The company has received funding, including a recent grant of $425,000 in October 2024, which supports their ongoing development and innovation in drug delivery systems. With a workforce of approximately 69 employees, ApiJect operates primarily in the United States, with additional presence in the UK, Switzerland, and Israel.

14. Medinstill Development LLC

• Website: medinstill.com
• Ownership type: Private
• Headquarters: New Milford, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1986
• Headcount: 11-50
• LinkedIn: medical-instill-technologies-inc-

Medinstill Development LLC, founded in 1986 and based in New Milford, Connecticut, is a private company with a workforce of approximately 26 employees. The firm specializes in the design and manufacture of sterile delivery systems and technologies tailored for the healthcare and pharmaceutical industries. Their product lineup includes advanced sterilization technologies, filling systems, and dispensing devices, all aimed at ensuring the highest standards of safety and efficacy for medical products. Medinstill's clientele includes healthcare providers and pharmaceutical companies that require reliable sterile solutions. The company has also engaged in strategic partnerships to enhance vaccine delivery systems, showcasing its commitment to innovation and responsiveness to industry needs. Medinstill's INTACT™ technology, recognized by the FDA as a paradigm shift in aseptic filling, underscores its role in advancing pharmaceutical manufacturing practices.

15. Nalas Engineering Services, Inc.

• Website: nalasengineering.com
• Ownership type: Private
• Headquarters: Essex, Connecticut, United States (USA)
• Employee distribution: United States (USA) 97%, United Kingdom (UK) 3%
• Founded year: 2008
• Headcount: 11-50
• LinkedIn: nalas-engineering-services-inc.

Nalas Engineering Services, Inc., founded in 2008 and based in Essex, Connecticut, specializes in engineering services for the chemical and pharmaceutical industries. The company offers a comprehensive range of services, including synthesis and process development, process scale-up, manufacturing, and quality control. Nalas Engineering plays a crucial role in helping clients transition from laboratory-scale projects to commercial production, ensuring that safety and regulatory compliance are maintained throughout the process. With a team of experts in chemistry, analytical methods, chemical engineering, and pharmaceutical science, Nalas Engineering is positioned to deliver innovative solutions that enhance production efficiency and reduce costs. The company has recently expanded its capabilities with the establishment of a manufacturing line, further solidifying its commitment to supporting the pharmaceutical sector. Nalas Engineering has also engaged in various Small Business Innovative Research (SBIR) projects, showcasing its dedication to technological advancement in the industry.

16. AVS Bio

• Website: avsbio.com
• Ownership type: Private Equity
• Headquarters: Norwich, Connecticut, United States (USA)
• Employee distribution: United States (USA) 98%, Spain 2%
• Latest funding: January 2023
• Founded year: 1961
• Headcount: 201-500
• LinkedIn: avsbio

AVS Bio, based in Norwich, Connecticut, is a biotechnology company founded in 1961. Initially established as SPAFAS (Specific Pathogen Free Avian Supplies), the company has evolved into a prominent producer of Specific Pathogen Free (SPF) eggs and related laboratory products. These SPF eggs are vital for the development and manufacture of vaccines and therapeutics in both human and animal health markets. AVS Bio emphasizes stringent quality control and biosecurity measures, ensuring that their products meet the highest standards required for vaccine production. With over 60 years of experience, they have produced more than one billion SPF eggs and operate numerous production facilities across the United States. Their offerings include primary chicken embryo cells, diagnostic testing services, and custom cell production, all aimed at supporting the biopharmaceutical industry. In 2022, AVS Bio reestablished itself as an independent company after operating as a subsidiary of Charles River Laboratories for 30 years, marking a new chapter in its commitment to innovation and customer support.

17. Brand-Nu Laboratories, LLC

• Website: brandnu.com
• Ownership type: Private
• Headquarters: Meriden, Connecticut, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 1956
• Headcount: 11-50
• LinkedIn: brand-nu-laboratories-inc.

Brand-Nu Laboratories, LLC, established in 1956 and headquartered in Meriden, Connecticut, is a private company specializing in the distribution and manufacturing of high purity chemicals. The company operates globally, catering to customers in the pharmaceutical, biotechnology, and microelectronics sectors. Brand-Nu is known for its custom formulations, which are tailored to meet specific client requirements, ensuring high standards of quality and compliance. They have a robust portfolio that includes intermediates and active pharmaceutical ingredients (APIs), as well as a wide range of chemical products. In 2020, Brand-Nu became part of Caldic, a global specialty chemical distributor, enhancing its distribution capabilities and market reach. The company is ISO 9001:2015 registered, reflecting its commitment to quality management systems. Brand-Nu's facilities include a clean room for producing low impurity blends, which is crucial for applications in sensitive industries like pharmaceuticals. Their operational model emphasizes quick delivery and customer-specific solutions, making them a valuable partner in the pharmaceutical manufacturing process.

18. BAUSCH Advanced Technology Group

• Website: bausch-group.com
• Ownership type: Family Owned
• Headquarters: Clinton, Connecticut, United States (USA)
• Employee distribution: United States (USA) 57%, Brazil 40%, Germany 3%
• Founded year: 2007
• Headcount: 51-200
• LinkedIn: bausch-advanced-technology-group

BAUSCH Advanced Technology Group, founded in 2007 and based in Clinton, Connecticut, is a family-owned company that specializes in the design, manufacture, and servicing of custom aseptic fill-finish packaging equipment for the pharmaceutical and biotech sectors. With a workforce of approximately 97 employees, the company leverages over 55 years of engineering and manufacturing experience to deliver innovative solutions tailored to the specific needs of their clients. Their product offerings include filling machines, ready-to-fill IV bags, and single-use pathway kits, all produced in compliance with stringent industry standards. BAUSCH Advanced Technology Group also provides a range of services, including consulting, installation, maintenance, and retrofitting, ensuring that their clients receive comprehensive support throughout the lifecycle of their equipment. Their commitment to quality and customer satisfaction has established them as a reliable partner in the pharmaceutical manufacturing process.

19. Mantrose-Haeuser Co., Inc.

• Website: mantrose.com
• Ownership type: Private
• Headquarters: Fairfield, Connecticut, United States (USA)
• Employee distribution: United States (USA) 96%, Hong Kong S.A.R 4%
• Founded year: 1992
• Headcount: 51-200
• LinkedIn: mantrose-haeuser-co-inc-

Mantrose-Haeuser Co., Inc., based in Fairfield, Connecticut, is a private manufacturer established in 1992. The company specializes in edible coatings and specialty products that cater to various industries, including pharmaceuticals, food, and cosmetics. With a workforce of around 47 employees, Mantrose-Haeuser focuses on delivering high-quality solutions that enhance product performance and extend shelf-life. Their extensive product line for the pharmaceutical sector includes USP/NF and globally certified glazes, film coatings, seal coatings, and modified release ingredients. This positions them among the notable producers in the pharmaceutical manufacturing space. The company emphasizes innovation and sustainability, developing custom solutions tailored to meet the specific needs of their clients. Mantrose-Haeuser also collaborates with organizations like the USDA to create proprietary formulations, showcasing their commitment to research and development in the industry.

Pharmaceutical Manufacturing Insights: Key Companies in Connecticut

Want to Find More Pharmaceutical Manufacturing Companies?

With Inven you'll also get to know the company's:

• Detailed Ownership: Who owns the company? Is it a public or private company? What is the ownership structure?
• Contact data: Who are the founders and CEO's? What are their emails and phone numbers?
• Financials: How do these companies perform financially? What are their revenues and profit margins?

...and a lot more!